Royal Surrey study reveals digital frailty measure's impact on cancer treatment
A new digital tool could improve chemotherapy decisions
Researchers at Royal Surrey have conducted a major study indicating that a digital measure of frailty may aid doctors in determining the appropriateness of chemotherapy for cancer patients.
The research analysed health data from nearly 79,000 cancer patients throughout England.
It found that the Secondary Care Administrative Records Frailty (SCARF) Index can forecast survival and early mortality, especially for patients with breast and colorectal cancer.
Led by Professor Agnieszka Michael alongside colleagues from Royal Surrey and the University of Surrey, the study demonstrated that patients classified as frail through the SCARF index are significantly more likely to face negative outcomes following chemotherapy.
How the SCARF Index operates
Unlike conventional methods, which largely evaluate a patient's physical activity levels, the SCARF index uses routinely collected hospital data.
The study's findings have been published in The British Journal of Cancer under the title 'The utility of an electronic frailty index in cancer patients undergoing chemotherapy.'
Professor Michael highlighted the importance of recognising frailty in oncology, stating: “Frailty is often under-recognised in oncology and traditional tools don’t always capture the whole picture of a patient.
Digital tools like SCARF can help clinicians better match treatment to the individual and support more open, informed conversations about the risks and benefits of chemotherapy.
While there is more work to do, this represents an important step towards making frailty visible, measurable and actionable in everyday cancer care.”